A swarm of top biotech ex­ecs protest against Trump’s trav­el ban, say­ing it threat­ens the en­tire in­dus­try

The re­ac­tion against Pres­i­dent Trump’s de­ci­sion to ban trav­el from 7 pre­dom­i­nant­ly Mus­lim na­tions drew an in­stant re­ac­tion from the biotech world, gain­ing a quick thumbs-down from a large ma­jor­i­ty of the hun­dreds of in­dus­try ex­ec­u­tives we’ve been in touch with.

Now the biotech op­po­si­tion is get­ting or­ga­nized.

In a let­ter pub­lished in Na­ture Biotech­nol­o­gy this morn­ing, 166 biotech ex­ecs lev­eled a blast at Trump’s trav­el ban, now stayed at least tem­porar­i­ly by a court rul­ing, say­ing that it strikes at the heart of the in­dus­try’s abil­i­ty to re­cruit the best and bright­est staff from all over the world while rais­ing deep seat­ed fears among all their staffers from out­side the US.

The let­ter was signed by a long line­up of high-pro­file ex­ec­u­tives drawn from the CEO suite, ven­ture cap­i­tal and acad­e­mia, in­clud­ing Herve Hop­penot, the French CEO of Delaware-based In­cyte, George Scan­gos, the for­mer Bio­gen CEO who’s now lead­ing a start­up, and MIT’s Bob Langer, a se­r­i­al biotech en­tre­pre­neur with more than 30 star­tups to his cred­it.

“If this mis­guid­ed pol­i­cy is not re­versed,” they say, “Amer­i­ca is at risk of los­ing its lead­er­ship po­si­tion in one of its most im­por­tant sec­tors, one that will shape the world in the twen­ty-first cen­tu­ry.”

The let­ter un­der­scores the groundswell of op­po­si­tion in the in­dus­try to the ban. It al­so high­lights a grow­ing di­vide be­tween the ex­ec­u­tives who lead this field and BIO, the in­dus­try or­ga­ni­za­tion which lob­bies on their be­half. So far BIO has stayed mum about the trav­el ban.

(Ed­i­tor’s note: Late on Tues­day I re­ceived the fol­low­ing state­ment from BIO Chair Ron Co­hen and three board mem­bers, Je­re­my Levin, John Maraganore and Paul Hast­ings, tak­ing ex­cep­tion to that re­mark about BIO.

“We did want to high­light an in­ac­cu­ra­cy in your re­port re­gard­ing spec­u­la­tion that the let­ter re­flects a “grow­ing rift” be­tween BIO and its CEO and com­pa­ny mem­bers. There is no such rift, grow­ing or oth­er­wise; we are choos­ing to speak out on the ban as in­dus­try lead­ers, not as a trade as­so­ci­a­tion. This is not dis­sim­i­lar to how tech in­dus­try CEOs, not their trade as­so­ci­a­tion, have spo­ken out on this mat­ter. In­deed, we be­lieve that BIO is an es­sen­tial or­ga­ni­za­tion for the well-be­ing of our in­dus­try, which is why we all de­vote con­sid­er­able time out of our busy sched­ules to its ac­tiv­i­ties.”

My re­ply: Si­lence is a po­si­tion, and it’s marked­ly dif­fer­ent from what ex­ecs, in­clud­ing these board mem­bers, have ex­pressed.)

Most of the top CEOs of the Big Phar­ma com­pa­nies, many of whom have been lob­by­ing for tax re­form that would al­low them to repa­tri­ate bil­lions of dol­lars in re­serves held over­seas, have al­so stayed qui­et on this is­sue. But there was at least one ex­cep­tion to the Big Phar­ma rule of si­lence — aside from Al­ler­gan CEO Brent Saun­ders.

“Sci­ence doesn’t have any bor­ders, so any­thing that gets in the way of a bor­der­less sci­ence ex­change doesn’t help,” said As­traZeneca CEO Pas­cal So­ri­ot, quot­ed to­day by Bloomberg. The UK-based phar­ma gi­ant has re­search and man­u­fac­tur­ing sites in Mass­a­chu­setts and Mary­land. “We want to be able to move our peo­ple and our sci­en­tists around the world.”

The Bloomberg sto­ry al­so rais­es con­cerns that the Trump ad­min­is­tra­tion’s fo­cus on the H-1B visa pro­gram used to bring in sci­en­tists from around the world could be al­tered, mak­ing it hard­er to re­cruit abroad.

Here’s a por­tion of the let­ter:

The Unit­ed States has led the world in med­i­cine pro­duc­tion for decades, not on­ly be­cause of its abil­i­ty to fi­nance drug dis­cov­ery, but al­so be­cause, more than any oth­er coun­try, the Unit­ed States rep­re­sents op­por­tu­ni­ty re­gard­less of bor­ders, gen­der, race, sex­u­al ori­en­ta­tion or po­lit­i­cal cast. This has en­abled our in­dus­try to at­tract the best tal­ent, wher­ev­er it is found. This as­pect of our in­dus­try is a core rea­son the Unit­ed States has built its unique strength in bio­phar­ma­ceu­ti­cals.

At a stroke, the new ad­min­is­tra­tion has com­pro­mised years of in­vest­ment in this na­tion­al trea­sure. Our col­leagues who are here on visas or are in glob­al out­posts are now fear­ful and un­cer­tain of their sta­tus. Sci­en­tists based in oth­er coun­tries and em­ployed by our com­pa­nies are afraid to come to the Unit­ed States or are can­cel­ing trips. The par­ents and fam­i­lies of im­mi­grants who live and work in the Unit­ed States are re­luc­tant to at­tempt to trav­el to and from the US.

Though the ban from the Trump ad­min­is­tra­tion is aimed at sev­en coun­tries, our glob­al em­ploy­ees in­ter­pret the un­der­ly­ing mes­sage as, “Amer­i­ca is no longer wel­com­ing of any im­mi­grants, what­so­ev­er.” They fear sim­i­lar or­ders could be is­sued for oth­er coun­tries at a mo­ment’s no­tice. They fear be­ing stig­ma­tized and dis­crim­i­nat­ed against, sim­ply be­cause of their re­li­gion, ir­re­spec­tive of the na­tion they come from. Sev­er­al among us have heard from em­ploy­ees about their de­por­ta­tion fears, how they do not feel com­fort­able leav­ing the coun­try on busi­ness or how they now feel cut off from their fam­i­ly abroad.

Every na­tion has the right to de­ter­mine who comes across its bor­ders. Every na­tion needs to be vig­i­lant in de­fend­ing it­self against and hunt­ing down ter­ror­ists. The ac­tions tak­en by the Trump ad­min­is­tra­tion, how­ev­er, were poor­ly con­ceived and im­ple­ment­ed; they have raised deep fears and con­cerns across the biotech in­dus­try, in which di­ver­si­ty and the free flow of ideas and peo­ple have cre­at­ed an Amer­i­can pow­er­house of med­i­cine. 

If this mis­guid­ed pol­i­cy is not re­versed, Amer­i­ca is at risk of los­ing its lead­er­ship po­si­tion in one of its most im­por­tant sec­tors, one that will shape the world in the twen­ty-first cen­tu­ry. In­deed, it will harm an in­dus­try dom­i­nat­ed by small­er com­pa­nies and star­tups, the very kind of in­dus­try the ad­min­is­tra­tion has said it wants to sup­port. It will slow the fight against the many dis­eases that af­flict us, as well as car­ry neg­a­tive eco­nom­ic con­se­quences for the Unit­ed States.

You can find a PDF with the list of ex­ec­u­tives who signed the let­ter here: Im­mi­gra­tion Let­ter Sig­na­tures

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Kristen Hege, Bristol Myers Squibb SVP, early clinical development, oncology/hematology and cell therapy (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: Bris­tol My­er­s' Kris­ten Hege on cell ther­a­py, can­cer pa­tients and men­tor­ing the next gen­er­a­tion

Kristen Hege leads Bristol Myers Squibb’s early oncology discovery program carrying on from the same work at Celgene, which was acquired by BMS in 2019. She’s known for her early work in CAR-T, having pioneered the first CAR-T cell trial for solid tumors more than 25 years ago.

However, the eminent physician-scientist is more than just a drug developer mastermind. She’s also a practicing physician, mother to two young women, an avid backpacker and intersecting all those interests — a champion of young women and people of color in STEM and life sciences.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Gossamer Bio CEO Faheem Hasnain at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)

Gos­samer’s Fa­heem Has­nain de­fends a round of pos­i­tive PAH da­ta as a clear win. But can these PhII re­sults stand up to scruti­ny?

Gossamer Bio $GOSS posted a statistically significant improvement for its primary endpoint in the key Phase II TORREY trial for lead drug seralutinib on Tuesday morning. But CEO Faheem Hasnain has some explaining to do on the important secondary of the crucial six-minute walk distance test — which will be the primary endpoint in Phase III — as the data on both endpoints fell short of expectations, missing one analyst’s bar on even modest success.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mar­ket­ingRx roundup: Phar­mas lay off Twit­ter ads for an­oth­er week; WPP un­cov­ers LGBTQ+ mar­ket­ing find­ings

When Twitter’s new owner Elon Musk tweeted this weekend, “Just a note to thank advertisers for returning to Twitter,” he likely wasn’t talking about big pharma companies. The vast majority of the top spending pharma advertisers had not returned last week, according to updated tracking data Pathmatic for Endpoints News.

Only three pharma advertisers spent any money at all, which is about the same as the past several weeks. AstraZeneca rejoined the active advertiser list, although at $700 spent hardly worth a personal Musk expression of gratitude. GSK remained active with $3,500 spent ad much lower than its previous spending, according to the Pathmatics data. Only Bayer spent any significant amount in advertising, with $244,000 spent last week, but that’s a considerable drop from almost $500,000 spent on OTC, prescription and corporate Twitter ads in each of the previous two weeks.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.

Rick Modi, Affinia Therapeutics CEO

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Therapeutics has ditched its plans to go public in a relatively closed-door market that has not favored Nasdaq debuts for the drug development industry most of this year. A pandemic surge in 2020 and 2021 opened the doors for many preclinical startups, which caught Affinia’s attention and gave the gene therapy biotech confidence in the beginning days of 2022 to send in its S-1.

But on Friday, Affinia threw in the S-1 towel and concluded now is not the time to step onto Wall Street. The biotech has put out few public announcements since the spring of this year. Endpoints News picked the startup as one of its 11 biotechs to watch last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.

Bob Duggan, Summit Therapeutics co-CEO

Bounc­ing from ma­jor set­back, Sum­mit hands out $500M cash for can­cer drug — thanks to a loan from bil­lion­aire CEO

After hitting a dead end with Summit Therapeutics’ lead program, Bob Duggan has found the drug that he believes will usher into a compelling second act. So compelling, in fact, that it involves $500 million cash — and he’s taking money out of his own pocket to fund the deal.

Striking a partnership with Akeso Therapeutics out of China, Summit is bringing in a bispecific antibody that blocks both PD-1 and VEGF called ivonescimab. Akeso, which has a PD-1/CTLA-4 bispecific approved in China, has already taken ivonescimab into multiple clinical trials, including a Phase III in lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.

Jay Lichter, Arialys Therapeutics CEO (Avalon Ventures)

Scoop: Aval­on, MPM back new CNS biotech with sci­en­tif­ic chops from Astel­las

A preclinical central nervous system biotech is in the works in La Jolla, CA, and the drug developer has reeled in capital from a syndicate of investors, Endpoints News has learned.

Arialys Therapeutics filed incorporation documents in the Golden State last December and applied its name for trademark protection with the US Patent and Trademark Office the week prior to that. Paperwork with the SEC also outlines plans to offer up equity in exchange for $55 million.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Daniel Gold, MEI Pharma CEO (via website/Vimeo)

As FDA door shuts on its PI3K, MEI Phar­ma throws in the tow­el, lays off staff

Having steered a PI3K inhibitor from preclinical studies all the way to Phase II, San Diego’s MEI Pharma is all but washing its hands of the drug as the FDA raises the bar on the class.

The biotech is discontinuing development of zandelisib everywhere except Japan, where its partner Kyowa Kirin will move forward with ongoing trials and explore an approval based on Phase II data. While MEI Pharma had originally hoped to do the same in the US, the FDA put its foot down and asked for a new clinical trial — which it decided isn’t worth the effort.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er makes an­oth­er bil­lion-dol­lar in­vest­ment in Eu­rope and ex­pands again in Michi­gan

Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe.

The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over the past year. As a major piece of the manufacturing network for Covid-19 vaccines and antivirals, Pfizer is gearing up to place more money into the site. Pfizer announced it will place $750 million into the facility, mainly to establish “modular aseptic processing” (MAP) production and create around 300 jobs at the site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.